GlassScriptPhysician profile
Margret Levin
NPI 1043468325
$12,064.99
in general payments reported to CMS, 2019-2025
38 companies · $2,347 in 2025
The $2,347 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,284 · 2022: $2,302 · 2023: $2,153 · 2024: $2,979 · 2025: $2,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,471 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,470.82 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,640.50 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,178.83 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $777.21 | 2021-2025 | Xifaxan |
| Amgen INC. | $715.95 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $657.34 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Genzyme Corporation | $599.88 | 2021-2025 | |
| Novo Nordisk INC | $532.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $456.20 | 2021-2025 | Unithroid, Rytary |
| Astrazeneca Pharmaceuticals LP | $367.80 | 2021-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $361.85 | 2021-2024 | Verquvo, Steglatro, Belsomra |
| Sumitomo Pharma America, INC. | $341.70 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $315.95 | 2022-2024 | Trelegy Ellipta |
| Scilex Pharmaceuticals INC. | $250.24 | 2021-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $245.65 | 2021-2023 | |
| Ardelyx, INC. | $211.72 | 2024 | Ibsrela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margret Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.